MIL 95
Alternative Names: CM-312; MIL-95Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Beijing Mabworks Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 02 Jun 2023 Adverse events data from a phase I trial in Lymphoma and Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)